Cargando…

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

SIMPLE SUMMARY: The treatment of high-risk neuroblastoma patients with anti-GD2 antibodies has improved survival, and it is an established treatment strategy; however, many patients still experience a late relapse. One disadvantage of passive immunotherapy is the absence of a memory response. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klingel, Leah, Siebert, Nikolai, Troschke-Meurer, Sascha, Zumpe, Maxi, Ehlert, Karoline, Huber, Stefanie, Loibner, Hans, Mutschlechner, Oliver, Lode, Holger N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735439/ https://www.ncbi.nlm.nih.gov/pubmed/36497290 http://dx.doi.org/10.3390/cancers14235802

Ejemplares similares

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
por: Marx, Madlen, et al.
Publicado: (2018)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report
por: Lode, Holger N., et al.
Publicado: (2019)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells
por: Forkel, Hannes, et al.
Publicado: (2022)

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
por: Schriegel, Felix, et al.
Publicado: (2021)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Idiotypic regulation of the immune system. Common idiotypic specificities between idiotypes and antibodies raised against anti- idiotypic antibodies in rabbits
Publicado: (1979)

Definition of T cell idiotypes using anti-idiotypic antisera produced by immunization with T cell clones
Publicado: (1982)

QUANTITATIVE INVESTIGATIONS OF IDIOTYPIC ANTIBODIES : III. PERSISTENCE AND VARIATIONS OF IDIOTYPIC SPECIFICITIES DURING THE COURSE OF IMMUNIZATION
por: MacDonald, A. Bruce, et al.
Publicado: (1970)

Thymic requirement for cyclical idiotypic and reciprocal anti-idiotypic immune responses to a T-independent antigen
Publicado: (1980)

A Possible Role for Idiotype/Anti-idiotype B–T Cell Interactions in Maintaining Immune Memory
por: Seledtsov, Victor I., et al.
Publicado: (2017)

Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses
Publicado: (1981)

Deposition of idiotype-anti-idiotype immune complexes in renal glomeruli after polyclonal B cell activation
Publicado: (1982)

Loss of tumor-specific and idiotype-specific immunity with age
Publicado: (1981)

Suppression of interstitial nephritis by auto-anti-idiotypic immunity
Publicado: (1982)

Immunoregulatory role of maternal idiotypes. Ontogeny of immune networks
Publicado: (1980)

Cellular basis of regulation of expression of idiotype. II. Immunity to anti-MOPC-460 idiotype antibodies increases the level of anti- trinitrophenyl antibodies bearing 460 idiotypes
Publicado: (1979)

Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones
Publicado: (1981)

ANTI-IDIOTYPE ANTIBODIES IN IMMUNE REGULATION OF ANCA ASSOCIATED VASCULITIS
por: Pradhan, Vandana D, et al.
Publicado: (2009)

Structural basis for the function of anti-idiotypic antibody in immune memory
por: Vani, J., et al.
Publicado: (2009)

Induction of specific transplantation immune reactions using anti- idiotypic antibodies
Publicado: (1978)

Immunization of mice against African trypanosomiasis using anti- idiotypic antibodies
Publicado: (1982)

Idiotypes on major histocompatibility complex-restricted virus-immune cytotoxic T lymphocytes
Publicado: (1981)

Idiotype-recognizing T helper cells that are not idiotype specific
Publicado: (1983)

Idiotype profile of an immune response. II. Reversal of the relative dominance of major and minor cross-reactive idiotypes in arsonate- specific T-independent responses
Publicado: (1983)

Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_cva6oon5njk7eiv27dcjibh2tr